Full-Time

Senior Software Quality Engineer

DEKA Research & Development Corp.

DEKA Research & Development Corp.

501-1,000 employees

Independent R&D lab developing medical devices

No salary listed

Manchester, NH, USA

In Person

Bachelor's, Master's

Category
QA & Testing (1)
Required Skills
Microsoft Office
Software Testing
Visio
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to DEKA Research & Development Corp.

See people who can refer or advise you

Requirements
  • A Master of Science or Bachelor of Science degree in Engineering, Computer Science, or a related discipline.
  • At least 5 years of experience in an FDA-regulated industry.
  • Working knowledge of FDA Quality System Management Requirements, ISO 62304, and GAMP 5.
  • Organization, communication, and technical leadership skills.
  • Proficiency with Microsoft Office tools, including Word, Excel, PowerPoint, and Visio.
  • Ability to clearly write procedures that others can easily follow.
Responsibilities
  • Partner with Project Managers, System Engineers, Quality Systems Management, and Information Technology to support implementation of critical software tools.
  • Lead requirement capture discussions to convert users' needs into technical requirements.
  • Develop system-level test strategies, test specifications, and test protocols.
  • Perform hazards analysis, failure modes analysis, and mitigation design.
  • Support development and configuration of custom software tools.
  • Support device development teams through delivery of modern, validated software tools.
  • Use experience in software product development or software tool validation for medical devices to provide guidance and assistance.
Desired Qualifications
  • Experience with requirements definition and management for regulatory compliance.
DEKA Research & Development Corp.

DEKA Research & Development Corp.

View

DEKA Research & Development Corp. is a leading engineering R&D lab in Manchester, New Hampshire that develops a wide range of practical technologies and devices. It operates by interdisciplinary teams of engineers, machinists, designers, and technicians who take ambitious ideas and turn them into tangible products using advanced design and manufacturing methods. The company differentiates itself through its culture of hands-on experimentation, diverse project portfolio, and a track record of bringing to market or translating ideas into real-world applications. Its goal is to create technologies with a positive, lasting impact on people’s lives by solving meaningful problems.

Company Size

501-1,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Manchester, New Hampshire

Founded

1982

Get referred to DEKA Research & Development Corp.

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • October 2025 acquisition of Diatech diabetes IP deepens DEKA’s insulin-delivery moat.
  • July 2025 U.S. launch of twiist gives DEKA a live commercial reference customer.
  • The Emergex partnership expands optionality beyond diabetes into vaccine and immunotherapy delivery.

What critics are saying

  • February 2026 Epstein-review headlines drag Dean Kamen’s reputation onto DEKA’s brand.
  • Sequel still lacks a clear commercial scale-up timeline for twiist, limiting near-term revenue.
  • Failure in diabetes commercialization would leave DEKA dependent on partner-funded projects and Kamen’s capital.

What makes DEKA Research & Development Corp. unique

  • Dean Kamen’s 1982 engineering shop builds regulated drug-delivery hardware, not software demos.
  • DEKA’s twiist pump earned FDA clearance in April 2025 for ages six and older.
  • The 2024 Emergex collaboration shows DEKA’s intradermal platform can serve multiple therapeutic categories.

Help us improve and share your feedback! Did you find this helpful?

Company News

Emergex Vaccines Holding Limited
Jan 16th, 2024
Emergex Announces R&D Collaboration with DEKA Research & Development Corp. for Assessment of Emergex's Immunotherapeutic Candidates with DEKA's Intradermal Therapeutic Applicator

- Emergex has entered into an agreement with DEKA Research & Development ('DEKA') to assess the compatibility of Emergex's T cell-priming set-point immunotherapeutic candidates with DEKA's Intradermal Therapeutic Applicator.

Business Wire
Oct 13th, 2022
Revolutionary And Affordable New Robotics System Makes Debut At 2022 First Global Challenge = A Win For Stem Equity

The XRP robot kits can help democratize robotics by getting younger generations excited about STEM and making the field of robotics more affordable and accessible in all parts of the world. The XRP robot kits can help democratize robotics by getting younger generations excited about STEM and making the field of robotics more affordable and accessible in all parts of the world